Chargement en cours...
Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL. To improve the induction remission rate, we modified the dose of idarubicin in the original Children's Cancer Group (CCG)-1884 protocol, and retrospecti...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Korean Academy of Medical Sciences
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2672129/ https://ncbi.nlm.nih.gov/pubmed/19399271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2009.24.2.281 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|